Major pharmaceutical firms to fare worse in Q3

Published: 2012-10-17 06:58:00

Updated: 2012-10-17 06:58:00

The outlook for Korean listed drug companies' third quarter earnings is taking a turn for the worse as the government forced down prices of medicines in April, a report showed Monday.

Hi Investment & Securities downgraded the third-quarter earnings outlook for major pharmaceutical companies, w...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK